Preclinical data have implicated cyclin D1/CDK4 in resistance to therapy in HER2+ breast cancer and the potential of CDK4/6i to overcome this resistance (19), providing rationale for the investigation of abemaciclib in combination with HER2-targeted therapy. The gene discussed is ERBB2; the disease is breast carcinoma.